Viridian Therapeutics Inc

NASDAQ:VRDN   3:01:20 PM EDT
18.43
+0.13 (+0.71%)
Products

Viridian Therapeutics Announces FDA Clearance Of Investigational New Drug Application For Vrdn-001, For Thyroid Eye Disease

Published: 11/15/2021 12:30 GMT
Viridian Therapeutics Inc (VRDN) - Viridian Therapeutics Announces FDA Clearance of Investigational New Drug (ind) Application for Vrdn-001, an Igf-1r Antibody for the Treatment of Thyroid Eye Disease (ted).
Viridian Therapeutics Inc - Expects to Announce Top Line Data From Proof of Concept Portion of Trial in Q2 of 2022.